- Home
- Products
- Customized ADCs
- NCAM1
- Anti-NCAM1 (clone huN901)-SPP-DM1 ADC
Anti-NCAM1 (clone huN901)-SPP-DM1 ADC (CAT#: ADC-W-460)
This ADC product is comprised of an Anti-NCAM1 antibody (clone huN901) conjugated via a SPP linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- Product Information
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Antibody clone #
- huN901
- Similar to
- Lorvotuzumab mertansine (IMGN901)
- Name
- NCAM1
- Alternative Names
- NCAM1; neural cell adhesion molecule 1; CD56; NCAM; MSK39; neural cell adhesion molecule, NCAM; antigen recognized by monoclonal antibody 5.1H11;
- Target Entrez Gene ID
- 4684
- Target UniProt ID
- P13591
- Overview
- This gene encodes a cell adhesion protein which is a member of the immunoglobulin superfamily. The encoded protein is involved in cell-to-cell interactions as well as cell-matrix interactions during development and differentiation. The encoded protein has been shown to be involved in development of the nervous system, and for cells involved in the expansion of T cells and dendritic cells which play an important role in immune surveillance. Alternative splicing results in multiple transcript variants.
- Overview
- Anti-NCAM1 lgG1 Antibody, clone # huN901
- Generic name
- Lorvotuzumab
- Clone #
- huN901
- Species Reactivity
- Human
- Name
- SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)
- Description
- Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.
- Name
- DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
- Description
- Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-TGFB1 (Fresolimumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1799)
- Anti-MSLN (clone h7D9.v3)-Mc-VC-PABC-MMAE ADC (CAT#: ADC-W-455)
- Anti-TNC (Tenatumomab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1818)
- Anti-MUC1 (clone huC242)-PEG4Mal-DM1 ADC (CAT#: ADC-W-313)
- Anti-IL2RA (Daclizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1373)
- Anti-TNF (Golimumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1823)
- Anti-CD80 (Galiximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-961)
- Anti-IFNA1 (Faralimomab)-SPDB-DM4 ADC (CAT#: ADC-W-1221)
- Anti-CD200 (Samalizumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-792)
- Anti-NGcGM3 (Racotumomab)-SMCC-DM1 ADC (CAT#: ADC-W-2264)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-460. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-2342 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2621 | Anti-NCAM1 (Lorvotuzumab )-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2620 | Anti-NCAM1 (Lorvotuzumab )-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-599 | Anti-CD56 (clone huN901)-SPDB-[3H]DM1 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | [3H]DM1([3H]N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine) |
ADC-W-2623 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
CAT# | Product Name | Linker | Payload |
ADC-W-625 | Anti-CD22 (10F4v3)-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-230 | Anti-MUC1 ( huC242)-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-613 | Anti-CD19 (B496)-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-621 | Anti-CR2 (THB-5)-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-572 | Anti-ERBB2 (Trastuzumab-Fab)-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-AA-008 | anti-HIgG(Fc)-N-DM1 ADC | Noncleavable linkers | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-603 | Anti-FOLH1 (clone J591)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-AA-031 | anti-MIgG(Fc)Fab-N-DM1 ADC | Noncleavable linkers | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-541 | Anti-CD44 (clone BIWA 4)-DM1 ADC | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | |
ADC-W-582 | Anti-ERBB2-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.